Media headlines about Bioamber (NYSE:BIOA) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioamber earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.2004212987487 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Beta factor is Very High in this Stock: BioAmber Inc. (BIOA) (wallstreetinvestorplace.com)
- Global Succinic Acid Market Size 2018 – Natureworks LLC, Bioamber, Succinity and Myriant Corporation (thefinancialconsulting.com)
- Methyl Isobutyl Ketone (MIBK) Market Global Overview 2018- BioAmber Inc (Canada), BASF SE (Germany) (factsweek.com)
- Green and Bio Solvents Market Global Overview 2018- Bioamber Inc, Dupont, BASF SE (factsweek.com)
- Global Bio-Plasticizers Market Analysis Report 2018 – Evonik Industries, Bioamber, Lanxess Ag, Danisco and Dow … (thetechnicalprogress.com)
BIOA has been the subject of several recent analyst reports. ValuEngine raised Bioamber from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Zacks Investment Research raised Bioamber from a “sell” rating to a “hold” rating in a research note on Monday, February 19th. Finally, HC Wainwright decreased their target price on Bioamber from $12.00 to $1.75 and set a “buy” rating for the company in a report on Thursday, March 29th.
NYSE BIOA traded down $0.00 during trading on Tuesday, reaching $0.03. 520,457 shares of the company’s stock were exchanged, compared to its average volume of 3,141,723. The company has a quick ratio of 0.75, a current ratio of 1.08 and a debt-to-equity ratio of 0.24. Bioamber has a 1 year low of $0.02 and a 1 year high of $2.88.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/04/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-bioamber-bioa-stock-price.html.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.